- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 853083, 6 pages
Vaccine Adverse Events Reported during the First Ten Years (1998–2008) after Introduction in the State of Rondonia, Brazil
1Department of Nursing, Fundação Universidade Federal de Rondônia, 76801-974 Porto Velho, RO, Brazil
2Faculty of Health Sciences, Universidade de Brasília, 70919-970 Brasilia, DF, Brazil
3Universidade Federal do Rio de Janeiro, Campus Macaé, 27971-550 Rio de Janeiro, RJ, Brazil
4Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil
Received 2 October 2012; Revised 7 January 2013; Accepted 11 January 2013
Academic Editor: Tanjore Balganesh
Copyright © 2013 Mônica P. L. Cunha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. R. Hinman, W. A. Orenstein, and A. Schuchat;, “Centers for Disease Control and Prevention (CDC). Vaccine-preventable diseases, immunizations, and MMWR—1961–2011,” MMWR Surveillance Summary, vol. 60, supplement 4, pp. 49–57, 2011.
- G. A. Poland, I. G. Ovsyannikova, and R. M. Jacobson, “Adversomics: the emerging field of vaccine adverse event immunogenetics,” Pediatric Infectious Disease Journal, vol. 28, no. 5, pp. 431–432, 2009.
- R. T. Chen, “Vaccine risks: real, perceived and unknown,” Vaccine, vol. 17, no. 3, pp. S41–S46, 1999.
- R. T. Chen, V. Pool, H. Takahashi, B. G. Weniger, and B. Patel, “Combination vaccines: postlicensure safety evaluation,” Clinical Infectious Diseases, vol. 33, no. 4, pp. S327–S333, 2001.
- D. S. Diekema, “Improving childhood vaccination rates,” The New England Journal of Medicine, vol. 366, no. 5, pp. 391–393, 2012.
- E. Autret-Leca, L. Bensouda-Grimaldi, A. P. Jonville-Béra, and F. Beau-Salinas, “Pharmacovigilance of vaccines,” Archives de Pediatrie, vol. 13, no. 2, pp. 175–180, 2006.
- W. Zhou, V. Pool, J. K. Iskander et al., “Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001,” MMWR Surveillance Summaries, vol. 52, no. 1, pp. 1–24, 2003.
- R. T. Chen, S. C. Rastogi, J. R. Mullen et al., “The vaccine adverse event reporting system (VAERS),” Vaccine, vol. 12, no. 6, pp. 542–550, 1994.
- E. A. Waldman, K. R. Luhm, S. A. M. G. Monteiro, and F. R. M. de Freitas, “Surveillance of adverse effects following vaccination and safety of immunization programs,” Revista de Saude Publica, vol. 45, no. 1, pp. 173–184, 2011.
- S. A. M. Gomes Monteiro, O. A. Takano, and E. A. Waldman, “Evaluation of the Brazilian surveillance system for adverse events following vaccination,” Revista Brasileira de Epidemiologia, vol. 14, no. 3, pp. 361–371, 2011.
- S. A. M. G. Monteiro, O. A. Takano, and E. A. Waldman, “Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting,” Vaccine, vol. 28, no. 18, pp. 3127–3133, 2010.
- J. G. Dòrea, “Breastfeeding is an essential complement to vaccination,” Acta Paediatrica, International Journal of Paediatrics, vol. 98, no. 8, pp. 1244–1250, 2009.
- G. Evans, “Vaccine injury compensation programs worldwide,” Vaccine, vol. 17, supplement 3, pp. S25–S35, 1999.
- C. Lookera and H. Kellya, “No-fault compensation following adverse events attributed to vaccination: a review of international programmes,” Bulletin of the World Health Organization, vol. 89, no. 5, pp. 371–378, 2011.
- D. A. Geier, L. K. Sykes, and M. R. Geier, “A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness,” Journal of Toxicology and Environmental Health—Part B, vol. 10, no. 8, pp. 575–596, 2007.
- K. Lapphra, L. Huh, and D. W. Scheifele, “Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination,” Pediatric Infectious Disease Journal, vol. 30, no. 1, pp. 84–86, 2011.
- J. G. Dórea, “Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines,” Neurochemical Research, vol. 36, no. 6, pp. 927–938, 2011.
- C. J. Clements, “The evidence for the safety of thiomersal in newborn and infant vaccines,” Vaccine, vol. 22, no. 15-16, pp. 1854–1861, 2004.
- J. G. Dórea, “Making sense of epidemiological studies of young children exposed to thimerosal in vaccines,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1580–1586, 2010.
- R. C. Marques, J. G. Dórea, J. V. E. Bernardi, W. R. Bastos, and O. Malm, “Prenatal and postnatal mercury exposure, breastfeeding and neurodevelopment during the first 5 years,” Cognitive and Behavioral Neurology, vol. 22, no. 2, pp. 134–141, 2009.
- D. Mrozek-Budzyn, R. Majewska, A. Kieltyka, and M. Augustyniak, “Neonatal exposure to Thimerosal from vaccines and child development in the first 3years of life,” Neurotoxicology and Teratology, vol. 34, no. 6, pp. 592–597, 2012.
- B. E. Lee and E. H. Ha, “Response to commentary ‘Co-exposure and confounders during neurodevelopment: we need them in the bigger picture of secondhand smoke exposure during pregnancy’,” Environmental Research, vol. 112, article 235, 2012.
- J. G. Dórea, R. C. Marques, and C. Isejima, “Neurodevelopment of Amazonian infants: antenatal and postnatal exposure to methyl- and ethylmercury,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 132876, 9 pages, 2012.
- Y. Tsuji, I. Ichihashi, K. Morita, and K. Itabashi, “Difference of the pain during the DPT (Diphtheria-Pertussis-Tetanus) vaccination,” World Journal of Vaccines, vol. 2, pp. 91–95, 2012.
- K. Terada, M. Inoue, T. Yamaguchi, S. Ogita, K. Kawasaki, and K. Ouchi, “Difference of response in an inoculation site and pain between vaccines with Thimerosal or Phenoxyethanol,” Infection and Immunity in Childhood, vol. 22, no. 2, pp. 145–150, 2010.
- J. G. Dórea, “Concern regarding early exposure to thiomersal and mercury poisoning: comment on the article by Bensefa-Colas et al,” Revue de Medecine Interne, vol. 33, no. 2, pp. 115–116, 2012.
- A. Katzav, S. Kivity, M. Blank, Y. Shoenfeld, and J. Chapman, “Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome,” Lupus, vol. 21, no. 2, pp. 210–216, 2012.
- E. Israeli, “Gulf War Syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvant (ASIA),” Lupus, vol. 21, no. 2, pp. 190–194, 2012.